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Motivation: Fusion genes created by genomic rearrangements can be potent drivers of tumorigenesis. 
However, accurate identification of functionally fusion genes from genomic sequencing requires whole 
genome sequencing, since exonic sequencing alone is often insufficient. Transcriptome sequencing 
provides a direct, highly effective alternative for capturing molecular evidence of expressed fusions in the 
precision medicine pipeline, but current methods tend to be inefficient or insufficiently accurate, lacking in 
sensitivity or predicting large numbers of false positives. Here, we describe STAR-Fusion, a method that is 
both fast and accurate in identifying fusion transcripts from RNA-Seq data. 
Results: We benchmarked STAR-Fusion’s fusion detection accuracy using both simulated and genuine 
Illumina paired-end RNA-Seq data, and show that it has superior performance compared to popular 
alternative fusion detection methods. 
Availability and implementation: STAR-Fusion is implemented in Perl, freely available as open source 
software at http://star-fusion.github.io, and supported on Linux. 
Contact: bhaas@broadinstitute.org  
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Introduction 
 
Major efforts are underway to dissect the molecular underpinnings of cancer development, progression, 
evolution, and resistance to therapies (Cancer Genome Atlas Research, et al., 2013; International Cancer 
Genome, et al., 2010).  Research has shown there are many paths to tumorigenesis, often involving genetic 
mutations leading to activation of oncogenes and inactivation of tumor suppressors (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011). Chromosomal rearrangements leading to the formation of 
fusion transcripts represent one class of genomic aberrations that occur at high frequencies in certain cancer 
types, including leukemias and prostate cancer (Yoshihara, et al., 2015), as well as produce strong genetic 
drivers of the disease across a wide range of cancers (Stransky, et al. 2014).  Among the known cancer-
driving fusion transcripts with high prevalence in specific cancer types are BCR—ABL1, found in ~95% of 
chronic mylogenous leukemia patient samples (Lim, et al., 2005), TMPRSS2—ERG in ~50% of prostate 
cancers (Tomlins, et al., 2005), and DNAJB1—PRKACA found to be the hallmark and likely driver of 
fibrolamellar carcinoma, a rare liver tumor affecting young individuals (Honeyman, et al., 2014). 
Determining the driver of a given tumor is important to inform the best therapeutic strategy and match 
drugs effective against certain oncogenic fusions with the patients who could benefit from them. For 
example, tyrosine kinase inhibitors have been highly effective in the treatment of tumors harboring kinase 
fusion transcripts in leukemia and other cancers (Zhao, et al., 2015) (Shaw and Solomon, 2015) (Druker, et 
al., 2006) (Gross, et al., 2015).   
 
Genome and transcriptome sequencing are powerful methods to capture evidence for chromosomal 
rearrangements and fusion transcripts. Unlike point mutations and indels, which can be readily captured 
from efficient Whole Exome Sequencing (WES), genome sequencing evidence for fusion genes typically 
requires Whole Genome Sequencing (WGS). Conversely, transcriptome sequencing by RNA-Seq is highly 
suited for fusion transcript detection, since it represents the “expressed exome” of the tumor itself: it 
captures only the transcriptionally active regions of the genome, reflects any rearrangements, and reduces 
sequencing costs compared to WGS, thus focusing fusion-finding efforts on actively transcribed gene 
fusions that are most likely relevant to tumorigenesis.  
 
Several bioinformatics methods and software tools have been developed to identify candidate fusion 
transcripts from RNA-Seq (reviewed in (Latysheva and Babu, 2016; Wang, et al., 2013)). The general 
strategies fall into two conceptual classes: mapping-first approaches that align RNA-Seq reads to genes and 
genomes to identify discordantly mapping reads suggestive of rearrangements, and assembly-first 
approaches that directly assemble reads into longer transcript sequences followed by identifying chimeric 
transcripts consistent with chromosomal rearrangements. Evidence supporting predicted fusions is typically 
measured by the number of RNA-Seq fragments found as split (junction) reads that directly overlap the 
fusion transcript chimeric junction, or as spanning fragments (bridging read pairs) where each paired read 
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maps to opposite sides of the chimeric junction without directly overlapping the chimeric junction itself 
(shown in Figure 1).  
 
Implementations of the various prediction methods vary in the read alignment tools, the genome database 
and gene set resources used, criteria for reporting candidate fusion transcripts and excluding false positives, 
all resulting in varying prediction accuracies in addition to installation complexity, execution time, 
robustness, and hardware requirements. Depending on the fusion prediction tool chosen, processing a 
single RNA-Seq sample containing tens of millions of reads can take several days worth of computing and 
result with a list of hundreds to thousands of gene fusion candidates, most of which are likely false, having 
little evidence supporting their prediction.  Faster and more accurate methods for fusion detection are 
urgently needed, particularly as RNA-Seq ventures into the realm of precision medicine and clinical care. 
 
A critical component of mapping-first approaches is the read alignment step. In particular, the STAR 
aligner was originally developed as a fast and accurate RNA-Seq alignment tool with capabilities to report 
split reads and discordantly aligned pairs (Dobin, et al., 2013; Dobin and Gingeras, 2015; Dobin and 
Gingeras, 2016). Based on these capabilities, STAR was incorporated into a fusion detection pipeline to 
explore the landscape of kinase fusion transcripts in cancer (Stransky, et al., 2014), demonstrating that 
STAR could be leveraged to identify novel driver fusion transcripts. STAR has since been incorporated 
into ensemble fusion prediction pipelines (Nicorici, et al., 2014).  
 
Here, we describe STAR-Fusion – a fusion prediction tool leveraging the speed and accuracy of the STAR 
RNA-Seq aligner. STAR-Fusion builds upon and significantly expands a previously described successful 
strategy for calling fusions (Stransky et al, 2014), and is implemented here as a freely available open source 
software tool. STAR-Fusion performs a fast mapping of fusion evidence to reference transcript structure 
annotations and filters likely artifacts to report accurate fusion predictions. We demonstrate that STAR-
Fusion provides accurate fusion transcript prediction using both simulated and genuine RNA-Seq data 







The STAR-Fusion pipeline (Figure 1) takes Illumina RNA-Seq data (ideally paired-end, but compatible 
with single-end data) as input and generates lists of candidate fusion transcripts as output.  It also requires 
several genomic resources which are packaged into a Genome Resource Lib: the reference genome, 
reference transcript structure annotations, and results from an all-vs-all BLAST+ (Camacho, et al., 2009) 
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search of reference transcript sequences.  The Genome Resource Lib is compiled once for a given set of 
genomic resources and simply pointed to as a parameter to STAR-Fusion at run time.  Genome Resource 
Libs are provided for human and mouse, and instructions and software are available to facilitate compiling 
a new Genome Resource Lib for a different reference genome or different reference transcript annotation 
set (below). We discuss each of the components in turn. 
 
Aligning RNA-Seq reads to the genome using STAR, capturing split and discordantly mapping reads 
 
The chimeric detection in STAR is implemented as an extension of the STAR standard mapping procedure. 
In the first step, the maximum mappable prefix algorithm is used to find the seeds exactly matching to the 
genome. Next, genomic alignment windows are selected by clustering the anchor seeds, which are defined 
as those mapping to the genome fewer times than a user-defined parameter (--
winAnchorMultimapNmax=50 by default). The maximum window size determines the maximum genomic 
length of the local alignment, and is controlled by --alignMatesGapMax and --alignIntronMax. In each 
genomic window, a local alignment of the read sequence is performed by stitching together all seeds within 
the window. If the best alignment among all windows does not cover the entire read sequence, chimeric 
detection is performed by finding the next best scoring window that covers the remainder of the read 
sequence. Thus, the resulting chimeric alignment consists of two “segments”, each being a local linear 
alignment, with the minimum lengths restricted by --chimSegmentMin to prevent output of unreliable 
chimeras with short alignments. If a chimeric segment contains an intervening splice junction proximal to 
the chimeric junction, the minimum sequence segment length for the chimeric junction-proximal segment 
is specified by --chimJunctionOverhangMin. The maximum unmapped read sequence in-between two 
chimeric segments is limited by --chimSegmentReadGapMax.  
 
The STAR-Fusion mapping parameters are based upon the best practices for STAR (Dobin and Gingeras, 
2015; Dobin and Gingeras, 2016), as well as parameters optimized to capture fusion genes, as described 
above (Stransky, et al., 2014): 
    “STAR --chimSegmentMin 12 --chimJunctionOverhangMin 12 --chimSegmentReadGapMax 3 --
alignSJDBoverhangMin 10 --alignMatesGapMax 200000 --alignIntronMax 200000  --
alignSJstitchMismatchNmax 5 -1 5 5  --twopassMode Basic” 
 
Mapping split and discordant read alignments to reference gene annotations (STAR-Fusion.predict) 
 
To determine the candidate gene pairs of potential fusions, the discordant read pairs and split read 
alignments reported by STAR are next mapped to exons of reference transcript annotations based on 
coordinate overlaps, leveraging interval tree data structures (as implemented in the Perl CPAN module 
Set::IntervalTree (http://search.cpan.org/~benbooth/Set-IntervalTree-0.01/lib/Set/IntervalTree.pm) for fast 
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coordinate overlap queries. STAR-Fusion selects those candidate gene pairs for which the fusion-
supporting evidence indicates a sense-sense orientation between the fusion pairs and scores them according 
to the number of split reads supporting the fusion breakpoint and the number of paired-end fragments that 
span the breakpoint. Duplicate paired-end read alignments are removed.  
 
While most filtering of fusion candidates is performed by the STAR-Fusion.filter step as described below, 
some initial filtering based on read support is performed here simply to remove the weakest supported 
candidates and limit the subsequent more rigorous STAR-Fusion.filter step to a smaller number of 
candidates. This improves overall computing efficiency and reduces unnecessary input/output. STAR-
Fusion applies minimal read support criteria of at least one junction-defining split read and at least two total 
supporting fragments (sum of junction reads and spanning fragments). If the chimeric junction occurs at a 
position that does not coincide with a reference annotated exon splice junction, then at least three 
breakpoint reads are required. All minimal support criteria are configurable as program parameters.   
 
Filtering fusion predictions (STAR-Fusion.filter) 
 
Finally, STAR-Fusion determines the most likely correct fusions, filtering out unlikely candidates from the 
initial predictions. To this end, the candidates are further grouped according to gene pairings and 
breakpoint proximity and then further filtered according to read support, extent of alignment at the putative 
breakpoint, and sequence similarity between putative fusion gene partners, performed in the following 
order: 
 
1. Grouping by breakpoint proximity. Fusions with non-reference breakpoints that fall within a 
window of +/-5 bases of a dominantly supported breakpoint are merged into single fusion predictions with 
the dominant breakpoint.   
2. Assessing strength of alignment evidence. Those fusions that have only split-read support 
(lacking spanning fragment support) are required to have at least 25 bases of read alignment at each end of 
the breakpoint, though not necessarily from a single read, as different reads can provide the required 
alignment overlap at either end.   
3. Filtering lowly supported fusion isoforms. If multiple fusion isoforms are predicted for a given 
gene pair, we discard those isoforms having less than 10% of split-read supporting evidence compared to 
the dominantly supported breakpoint.   
4. Filtering sequence-similar fusion pairs. We exclude fusion candidates A—B where there exist a 
significant sequence alignment (BLAST, E<=10-3) between any two reference isoforms of the genes. 
Instead of performing BLAST at runtime, the results from an all-vs-all BLAST search are stored and 
indexed for immediate retrieval at runtime. 
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5. Filtering promiscuous fusion partners. Finally, promiscuous fusion genes, defined as those gene 
partners found to have multiple fusion partners predicted within a single sample, are filtered in two stages: 
first, those fusions containing a fusion gene that has less than 20% supporting evidence than a dominant 
fusion pair containing that same gene are discarded; second, any fusion pair containing a partner observed 
in at least 3 remaining fusion predictions are altogether excluded.   
 
Those fusions that pass the above filters are reported in a tab-delimited summary file identifying the fusion 
pairs, the inferred fusion breakpoint (chromosomal exon boundaries), counts of supporting split reads and 
spanning fragments, and identification of the RNA-Seq reads that support the fusion prediction. 
 
Compiling a Genome Resource Lib 
 
Compiling a Genome Resource Lib for use with STAR-Fusion requires three inputs:  (1) a reference 
genome in FASTA format, (2) reference transcript structure annotations in GTF format, and (3) results 
from an all-vs-all BLAST search of repeat-masked transcript sequences. Note that repeat masking is 
required in order to avoid detecting sequence similarities between transcripts that derive from mobile 
elements and other repeats that often occur within noncoding regions such as within lncRNAs or 
untranslated regions of otherwise unrelated coding transcripts. The results from the all-vs-all BLAST 
search are stored into a Berkeley DB for fast querying based on gene identifiers. We provide full 
instructions and helper utilities for building the Genome Resource Lib at http://fusionfilter.github.io . 
 
In the work described here, the Genome Resource Lib was constructed with the reference genome and 
transcript annotations in Gencode Release 19 (https://www.gencodegenes.org/releases/19.html), and 
restricted to the reference chromosomes (1-22, X, Y, and MT). Reference transcript sequences were 
reconstructed based on the GTF annotation file and then repeat masked using RepeatMasker (Smit A.F.A)  
as follows:   
    “RepeatMasker -pa 6 -s -species human -xsmall ref_annot.cdna" 
 
The repeat masked transcript sequences were then searched all-vs-all for sequence similarity using BLAST 
as follows: 
    “blastn -query ref_annot.cdna.masked -db ref_annot.cdna.masked -max_target_seqs 10000 -outfmt 6 -
evalue 1e-3 -lcase_masking  -num_threads 20 -word_size 11  >  blast_pairs.outfmt6” 
 
The genome was then indexed by STAR as follows: 
    “STAR --runThreadN 4 --runMode genomeGenerate --genomeDir ref_genome.fa.star.idx --
genomeFastaFiles ref_genome.fa --limitGenomeGenerateRAM 40419136213 --genomeChrBinNbits 16  
 --sjdbGTFfile ref_annot.gtf --sjdbOverhang 100” . 
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Benchmarking Fusion Prediction Accuracy 
 
We assessed fusion prediction accuracy using simulated and genuine RNA-Seq data, and compared it to 15 
previously developed methods. Specifically, we downloaded and installed each of PRADA (Torres-Garcia, 
et al., 2014), TopHat-Fusion (Kim, et al., 2013; Kim and Salzberg, 2011), deFuse (McPherson, et al., 2011), 
nFuse (McPherson, et al., 2012), EricScript (Benelli, et al., 2012),  ChimeraScan (Iyer, et al., 2011), 
FusionCatcher (Nicorici, et al., 2014), FusionHunter (Li, et al., 2011), JAFFA-Assembly, JAFFA-Hybrid, 
and Jaffa-Direct (Davidson, et al., 2015), SOAPfuse (Jia, et al., 2013), MapSplice (Wang, et al., 2010), 
ChimPipe (Rodriguez-Martin, et al., 2017), and InFusion (Okonechnikov, et al., 2016). To ensure 
consistency, we reconfigured SOAPfuse and TopHat-Fusion to leverage the Gencode v19 annotation. All 
fusion prediction methods with the exception of JAFFA-Assembly leverage read alignment to target 
reference genomes or transcriptomes, whereas JAFFA-Assembly first performs de novo assembly to 
reconstruct transcripts and then aligns the reconstructed transcripts to target sequences to identify likely 
fusions. JAFFA-Hybrid leverages both direct read mapping and de novo transcriptome assembly (Davidson, 
et al., 2015). Programs and parameters used are provided in Supplementary Table 1.  Benchmarking data, 
scripts, and the analysis protocols followed are provided at https://github.com/STAR-Fusion/STAR-
Fusion_benchmarking_data and in the Supplementary Text. 
 
 Simulated fusion transcripts and RNA-Seq data 
 
We generated simulated chimeric transcripts using custom scripts, developed and released here as the 
Fusion Simulator Toolkit (https://FusionSimulatorToolkit.github.io). FusionSimulator selects two protein-
coding genes at random from the Gencode v19 annotations. It then constructs a fusion transcript by 
randomly fusing a pair of exons randomly selected from each gene, requiring that each gene contributes at 
least 100 bases of transcript sequence to the generated fusion, and that the fusion breakpoint occurs 
between two exons that have consensus dinucleotide splice sites. In generating a set of fusion genes, any 
gene participating as a fusion partner is allowed to exist in only one fusion pair.   
 
We simulated RNA-Seq reads using ‘rsem-simulate-reads’ in the RSEM software (Li and Dewey, 2011). 
RSEM was first used to estimate the expression values of the Gencode v19 reference transcripts 
supplemented with the simulated fusion transcripts. Next, the expression values of the simulated fusion 
transcripts were reset randomly according to a log2 distribution of TPM expression values in the dynamic 
range of 1 to 15.  Simulated read lengths and read quality characteristics were modeled based on genuine 
RNA-Seq data sets as described below. After directly setting fusion transcript expression values, all 
transcript expression values were renormalized to TPM values (summing to 1 million) and subject to RNA-
Seq read simulation using ‘rsem-simulate-reads’.  
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This process was applied separately for ten samples, each generating 500 random fusions and simulating 30 
million PE Illumina RNA-Seq reads. Half of the simulated samples generated 50 base reads and the other 
half 101 base reads, the former modeled on short RNA-Seq reads generated by the Illumina Human Body 
Map 2.0 study (ArrayExpress study E-MTAB-513; http://www.ebi.ac.uk/arrayexpress), and the latter based 
on a set of cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) (Barretina, et al., 2012) 
(sources for the targeted data sets are listed in Supplementary Table 2).  Simulated fusion transcripts and 




Fusion prediction in cancer cell line transcriptomes 
 
Paired-end Illumina RNA-Seq data were obtained from 60 publicly available cancer cell line data sets, 
spanning a variety of cancer types (data sources and representative cancer types are listed in 
Supplementary Table 3). Cancer cell lines included 52 from the CCLE project, and further supplemented 
with 8 other cancer cell lines popularly studied for fusion detection including: the breast cancer cell lines 
BT474, KPL4, MCF7, and SKBR3 (Edgren, et al., 2011); VCaP (prostate cancer); LC2/ad and H2228 
(lung adenocarcinoma); and K562 (erythroleukemia). To facilitate benchmarking and runtime analysis, 20 
million paired-end reads were randomly sampled from each data set and targeted for fusion prediction.  All 




Fusion prediction accuracy computation 
 
True positive (TP), false positive (FP), and false negative (FN) fusion predictions were assessed for each 
method.  The true positive rate (TPR; or recall or sensitivity), positive predictive value (PPV, precision), 
and F1 accuracy measure (the harmonic mean of TPR and PPV) were computed according to standards: 
 
Recall = TPR = TP / (TP + FN) 
 
Precision = PPV = TP / (TP + FP) 
 
F1 = 2 * (TPR * PPV) / (TPR + PPV) 
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TP and FP were assessed at each minimum supporting evidence threshold to generate precision-recall 
curves, and prediction accuracy was measured as the area under the precision-recall curve (AUC), which is 
better suited than the popular receiver operating characteristic curve for studies such as fusion prediction 
where the numbers of true negatives (at least ~20k2, considering possible gene pairings) far exceeds the 
number of true positive fusions (Davis, 2006).  
 
Additional details regarding benchmarking methods, software, result files, and links to input RNA-Seq data 






STAR-Fusion accurately and sensitively predicts fusion on simulated data 
 
We compared STAR-Fusion and the 15 other methods on ten sets of simulated RNA-Seq data sets, each 
containing 30 M PE reads and each including 500 fusion transcripts expressed at a broad range of 
expression levels.  To examine the effect of read length on fusion prediction accuracy, half the samples 
contained 50 base reads and the other half contained 101 base reads, reflective of read lengths of 
contemporary RNA-Seq data sets. 
 
Most methods performed well on the simulated RNA-Seq data with high recall (TPR) and precision (PPV), 
with top contenders having slight differences in prediction accuracy (Figure 2a, Supplementary Tables 4-
7).  Most predictors had improved performance with longer (101 base) reads. Notably, JAFFA-Direct and 
JAFFA-Hybrid were restricted for use with longer reads (Davidson, et al., 2015).  Most fusions that were 
not captured had the lowest expression levels and hence had little to no corresponding read evidence.  
 
STAR-Fusion had superior accuracy with high sensitivity for fusion detection across the full dynamic range 
of gene expression (Figure 2, Supplementary Tables 4-8).  Since de novo assembly generally requires 
higher sequence coverage for transcript reconstruction and fusion detection, JAFFA-Assembly had limited 
sensitivity for fusion prediction. However, it is peculiar that JAFFA-Assembly demonstrated reduced 
sensitivity at the highest fusion transcript expression levels; this may result from JAFFA-Assembly using 
the Oases de novo transcriptome assembler, as similar approaches leveraging Trinity for de novo assembly 
continued to retain high sensitivity for the same highly expressed fusion transcripts (data not shown), and 
the assembly-free JAFFA-Direct did not exhibit this aberrant behavior.   
The vast majority of false positives obtained on the simulated data were due to paralogous genes of fusion 
transcripts being reported in addition to or in place of the known fusion gene; eg. Fusion A—B reported as 
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A’—B where A’ is a paralog of gene A. Scoring fusions containing paralogs as true positives improves 
reported prediction accuracies for all methods (Supplementary Fig 1), with STAR-Fusion continuing to 
demonstrate top performance.    
 
STAR-Fusion accurately and sensitively predicts fusions on cancer cell line transcriptomes 
 
Next, we compared the fusion transcript predictions of STAR-Fusion and each of the 15 methods in 60 
cancer cell line transcriptomes. Several of the 60 cell lines are well studied and include fusion transcripts 
that have been well documented and experimentally validated (Edgren, et al., 2011) (Suzuki, et al., 2013). 
Nevertheless, unlike with simulated data, there is no perfect truth set by which prediction accuracies can be 
computed with absolute certainty.  Instead, we used concordance between methods as a proxy for accuracy: 
we hypothesized that those fusions predicted by multiple different predictors are the most likely to be true 
and those uniquely predicted by a given predictor are more likely to be false.  Based on this concordance 
benchmarking approach, we defined the truth set as those fusions agreed upon by at least four different 
methods , and those uniquely predicted by a single method as false positives.  Those predictions agreed 
upon by only 2 or 3 methods were treated as ambiguous (neither TP nor FP).  
 
Unlike simulated data, there was much more substantial variation in the performance of different methods 
on the cancer cell line data, particularly in the numbers of putative FPs observed across methods (Figure 3, 
Supplementary Tables 9, 10).  The numbers of uniquely predicted fusions ranged from the tens to over a 
thousand at points of maximum prediction accuracy (peak F1 score in Figure 3D and Supplementary 
Table 9). Not all of the methods that performed well on simulated data were observed to excel on the 
cancer cell line data; for example, nFuse was among the top performers using simulated data (Figure 2), 
but lacked predictive power on the cancer cell line data (Figure 3).  
 
Nevertheless, STAR-Fusion was the top performing method on these data, having the highest AUC, 
followed by the recently published ChimPipe software.  Alternative definitions of truth sets might change 
the relative rankings of methods, but STAR-Fusion continues to demonstrate superior performance 
(Supplementary Figure 3 and Supplementary Text). For example, defining the truth set as fusions 
agreed upon anywhere between 2 and 5 methods, ignoring ambiguous predictions or treating ambiguous 
predictions as FP, and/or considering paralogs as proxies to TP predictions had no effect on STAR-Fusion's 
top ranking among all methods. 
 
Fusion prediction accuracy highly depends on the minimum threshold of evidence for split reads and 
junction-bridging fragments. For example, STAR-Fusion has peak accuracy on the cancer cell line data at a 
minimum of three total fusion-supporting RNA-Seq fragments (Figure 3D), whereas TopHat-Fusion 
reaches peak accuracy at a minimum of 5 fragments, but exhibits a steep decline in accuracy when 
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lowering the threshold to 3 fragments (Figure 3D), due to an influx of false positives with few additional 
true positives (Figure 3C). Notably, STAR-Fusion exhibited better performance across a range of 
minimum evidence thresholds (Figure 3D). In general, requiring at least 3 supporting RNA-Seq fragments 
per 20 M total reads (or normalized to 0.15 fusion fragments per million total RNA-Seq fragments (FFPM)) 
appears to provide near-optimal fusion prediction accuracy for the well-behaved prediction methods in this 
study. 
 
STAR-Fusion prediction pipeline is fast  
 
Finally, we compared the run time of each fusion prediction pipeline on conventional hardware leveraging 
the computing grid at the Broad Institute, with each of the 60 cancer cell line samples run as a separate 
compute job for each fusion prediction tool (Figure 4). Run times for fusion predictors on single samples 
(20 M PE reads) ranged from hours to days. 
 
STAR-Fusion has the shortest run time, taking on average 2.3 hours per sample, given a single compute 
core; STAR-Fusion can run at approximately 30 minutes per sample when provided with 10 compute cores 
(Supplementary Figure 4).  Most of STAR-Fusion’s execution time involves running STAR to align the 
RNA-Seq reads to the reference genome. Mapping the split read alignments and discordantly aligned pairs 
to the reference annotations and subsequent filtering of fusion candidates is comparably fast, taking only 9 





Fast and accurate fusion detection is essential to ensure progress in cancer research and to bring next-
generation sequencing to the precision medicine pipeline.  The National Cancer Institute Genomic Data 
Commons (https://gdc-portal.nci.nih.gov), current home for The Cancer Genome Atlas data, now contains 
RNA-Seq samples for over 10,000 tumors and totaling over 100 TB of data, and with current trends, the 
data deluge is expected to grow exponentially.  Further cancer genome sequencing is expected as it 
becomes more commonly deployed in the clinical setting and routinely used for treatment decision-making 
and prognostics (Gagan and Van Allen, 2015; Horak, et al., 2016).  We hope that the advances enabled by 
STAR-Fusion will enable it to play an important role in identifying known and actionable fusion transcripts 
in the clinical context, in addition to discovering new hallmarks of diverse cancer types in pan-cancer 
research studies.  
Fusion transcript discovery is just one aspect of the application of next-gen transcriptome sequencing to 
cancer research. RNA-Seq and genome read alignment already exist as standard methods in cancer 
sequencing studies.  Due to the fast speed and accuracy of the STAR aligner (Dobin, et al., 2013; Engstrom, 
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et al., 2013), STAR is already being used as a key component of production pipelines for aligning reads to 
genomes and estimating gene expression (https://www.encodeproject.org/pipelines/ENCPL002LPE/), and 
STAR is an integral component of the GATK best practices for variant calling using RNA-Seq data 
(https://software.broadinstitute.org/gatk/guide/article?id=3891). By enabling the STAR option to report the 
chimeric read alignments, these data will be readily available for running STAR-Fusion in the faster 
‘kickstart’ mode, and quickly provide access to lists of candidate fusion transcripts.  
 
STAR-Fusion is freely available as open source and included with documentation and sample data at 
http://star-fusion.github.io . We also provide access to running STAR-Fusion on user-provided RNA-Seq 
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Figure 1: Overview of the STAR-Fusion pipeline.  Illumina RNA-Seq reads are aligned to the genome 
using STAR. Discordant and split-read alignments are identified, mapped to reference transcript structure 
annotations, filtered to remove likely artifacts, and scored according to the abundance of fusion-supporting 
reads.  Fusion candidates containing sequence-similar gene pairs or promiscuous fusion partners are 
excluded as likely false positives. 
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Figure 2. Benchmarking of fusion prediction accuracy on simulated data. A. Distribution of precision-
recall AUC values for each predictor using short (blue, 50 base) or longer (red, 101 base) simulated reads. 
Boxplots show the distribution of AUC values among the 5 replicates, with the median drawn as the center 
line, boxes extending to the 1st and 3rd interquartile, and whiskers extending to furthest data points within 
1.5 * the interquartile range. B. Sensitivity of fusion prediction (recall) for simulated fusions at different 
expression levels.  Shows is the percent of simulated fusions (color bar) identified by each method (rows) 
at each expression level (log2(TPM)) bin, where bins range from 21 to 210. Ordering of rows in the heatmap 
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Figure 3. Benchmarking of fusion prediction accuracy on cancer cell line transcriptomes. A.  
Precision-recall curve AUC values for each method ranked from highest to lowest.  B.  Precision-recall 
curves from which AUC values were computed.  C. True positives (TP, Y axis) and false positives (FP, X 
axis) at each minimum fusion-supporting read evidence thresholds.  D. F1 accuracy measurements (Y axis) 
at each minimum read evidence thresholds (X axis). 
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Figure 4. Distribution of run times for fusion predictors on the 60 cancer cell line data sets.  Boxplots 
are drawn to represent the median, interquartile range, and whiskers drawn to furthest data points within 1.5 
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Supplementary	  Figure	  1:	  Fusion	  prediction	  TP	  and	  FP	  before	  and	  after	  treating	  paralogs	  of	  
true	  fusion	  partners	  as	  equivalent.	  	  The	  impact	  is	  most	  notably	  a	  decrease	  in	  the	  number	  of	  false	  
positives	  with	  a	  small	  increase	  in	  the	  number	  of	  true	  positives.	  Results	  are	  shown	  for	  the	  A.	  	  
simulated	  101	  base	  length	  PE	  reads	  and	  B.	  simulated	  50	  base	  length	  PE	  reads.	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Supplementary	  Figure	  2:	  Correlation	  of	  predicted	  fusion	  gene	  pairs	  among	  different	  fusion	  
prediction	  methods	  for	  the	  60	  cumulative	  cancer	  cell	  line	  data	  sets.	  	  Only	  JAFFA-­‐Direct	  and	  
JAFFA-­‐Hybrid	  demonstrate	  high	  correlation	  among	  predictions,	  and	  so	  JAFFA-­‐Hybrid	  was	  excluded	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Supplementary	  Figure	  3:	  	  Fusion	  prediction	  accuracy	  (AUC)	  computed	  using	  different	  truth	  set	  
definitions.	  	  The	  minimum	  threshold	  for	  the	  number	  of	  methods	  that	  must	  agree	  to	  define	  the	  truth	  
set	  is	  shown	  at	  left	  and	  ranges	  from	  2	  to	  5.	  	  True	  positive	  fusions	  are	  identified	  by	  strict	  gene	  identity	  
(A-­‐-­‐B)	  (left	  two	  columns)	  or	  allowing	  paralogs	  of	  fusion	  partners	  to	  suffice	  as	  proxies	  to	  the	  true	  
fusion	  partner	  (A'-­‐-­‐B'	  where	  A'	  is	  either	  A	  or	  a	  	  paralog	  of	  A,	  and	  B'	  is	  either	  B	  or	  a	  paralog	  of	  B).	  	  In	  all	  
cases,	  uniquely	  predicted	  fusions	  are	  treated	  as	  false	  positives.	  	  In	  the	  columns	  indicated	  'Ignore	  
Unsure',	  those	  predictions	  agreed	  upon	  by	  >1	  predictor	  and	  <	  threshold	  predictors	  are	  ignored	  and	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Supplementary	  Figure	  4:	  STAR-­‐Fusion	  runtime	  using	  multiple	  threads.	  	  The	  STAR	  aligner	  was	  
run	  as	  part	  of	  STAR-­‐Fusion	  with	  multithreading	  set	  to	  the	  specified	  number	  of	  threads	  and	  total	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